MicrofluidX raises £1.4m in seed funding to develop novel cell therapy bioprocessing technology
London, UK, 20th April 2020 / MicrofluidX announces it has raised £1.4m in seed funding from…read more
MicrofluidX is tackling the problems of process control, scalability, and cost associated with cell bioprocessing, in particular for autologous cell and gene therapy. Its automated, closed technology allows biologists to easily carry out process development by running dozens of cell culture conditions in parallel with extreme process control, and to scale up seamlessly up to several billion cells for manufacturing at a fraction of the current costs.
Associated Fund UK Innovation & Science Seed Fund
Sector Manufacturing / Engineering